Introduction
Glucocorticoids (GCs) play an integral role in a wide array of physiological systems in the body, affecting lipid and glucose metabolism, immunosuppressive and anti-inflammatory reactions, growth, reproduction and brain function. The effects of cortisol are largely mediated by the GC receptor (GR). In its unbound form, GR resides in the cytoplasm as part of a large multiprotein complex comprising of chaperones (hsp90, hsp70), co-chaperones, and immunophilins (FK506-binding protein) ( Fig. 1 ) [1] . Upon binding with cortisol, conformational changes occur, leading to the dissociation of GR from the multiprotein complex. GR-GR dimers are often formed. The activated, ligand bound GR complex then translocate to the nucleus, where it functions as a transcription factor to regulate gene expression by binding at specific glucocorticoid response elements regulating both transactivation or transrepression. The mechanism of transactivation of gene expression usually involves GR dimers, binding with specific glucocorticoid response elements and activating gene expression. The transrepression mechanism involves the activated GR interacting with transcription factors, like AP-1 and NF-kB, preventing them from binding to their target genes. This interaction can sometime allow GR to indirectly regulate gene expression The transrepression mechanism involves the activated GR interacting with transcription factors, like AP-1 and NF-kB, preventing them from binding to their target genes. This interaction can sometime allow GR to regulate gene expression indirectly in the absence of direct DNA binding [2, 3] .
Glucocorticoid receptor gene
The human GR gene (NR3C1) is located on chromosome 5 and consists of 9 exons (Fig. 2) . Variations in the transcription and translation of the GR gene can lead to seemingly random actions of cortisol. However, these variations are necessary to allows cells and tissues to appropriately adapt to wide concentrations of GC. As an example, alternative splicing of the GR precursor mRNA can give rise to 5 GR protein subtypes-GRa,GRb, GRg, GR-A and GR-P. Eight more receptor proteins are produced by alternative translation initiation from GR mRNA [4, 5] . The classic GRa isoform can increase GC sensitivity while the GRb is transcriptionally inactive and is responsible for GC resistance. In addition to the GR isoforms generated by alternative initiation of translation or alternative splicing, four novel receptor variants (GR NS-1, GR DL-1, GR-S1 and GR-S1 (À349A)) [6, 7] with multiple amino acid replacements/ truncation and unknown functional role have also been discovered. These generic variations may account for the diversity in patient presentations and responses to GC.
The role of GR expression, degradation and trafficking on glucocorticoid cellular responsiveness
The ability of GC to provoke cellular response is dependent on the GR expression, degradation, and translocation into the nucleus.
The intracellular concentration of GR varies greatly between different cells and tissues and involves a complex combination of regulatory feedback mechanisms at both the transcriptional and Fig. 1 . Glucocorticoid Receptors' Role in the Regulation of Gene Transcription: Unbound glucocorticoids (GCs) diffuse through the cell membranes binding to GC receptors (GR) residing in the cytoplasm as part of a large multiprotein complex comprising of chaperones (hsp90, hsp70) and immunophilins (FKBP5). The bioavailability of endogenous GCs at the cellular level is limited by enzymatic metabolism (11b-HSD enzymes). The activated GR then translocates to the nucleus to modulate the gene transcription process. Liganded GRs bind to four main types of GR-response elements (GREs): simple (+GRE), negative (nGRE), composite GREs (cGRE), and interactions (tGRE). The regulation of both transactivation and transrepression is dictated by the type of GRE and its binding partners.
post-transcriptional process. The presence of GC, level of GR protein and GR mRNA can either trigger an up-regulation or a down-regulation of GR depending of the cell type and its current stage of cellular development. Since the intensity of biological response is proportional to the concentration of GR, the variation in regulatory feedback mechanisms allow the cells to modulate their sensitivity to GC [8] .
However, binding to the GR can trigger a significant and rapid reduction in the half-life of the GR protein (18 h to 9 h) [9] . The degradation of GR through the ubiquitin-proteasomes pathway requires GR proteins to be covalently tagged with multiple ubiquitin moieties [10] . The additions of ubiquitin to the GR proteins are mediated by ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligase enzymes (E3).
The contributions of the ubiquitin enzymes to the GR degradation process are enzyme specific and may or may not be hormonally dependent. For example, in human breast cancer cell lines, GR degradation is triggered by estrogen through the induction of the E3HDM2 enzymes [11] . Conversely, in vitro studies have suggested that overexpression of E3CHIP [12] can resist hormone induced GR degradation and help restore GR. This suggests that the balance of specific ubiquitin enzymes is necessary in maintaining steady-state GR concentration.
To exert its biological action, the ligand bound GR has to translocate into the nucleus. However, GR trafficking from the cytoplasm to the nucleus is bidirectional. The ability of the receptor to translocate back and forth [13] is primarily regulated by proteins that serve as cytoplasmic anchors (molecular chaperones, dynein, and 14-3-3 proteins) [14, 15] . Additionally, in vitro studies have also shown that c-Jun N-terminal kinase (JNK), can enhance nuclear expulsion of GR limiting its transactivation properties [16] .The inability of GR to translocate into the nucleus can result in cellular resistance to GCs, as seen in patients with steroid-resistant or steroid-dependent asthma [17] .
Glucocorticoid receptor and metabolic syndrome
GCs acting through the GR regulate key enzymes of glucose metabolism in the liver, skeletal muscle, adipose tissue and the pancreas. In the liver, GCs regulate the expression of major gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase, glucose-6-phosphatase and tyrosine aminotransferase. In skeletal muscle, GCs play a major role in peripheral glucose utilization by interfering with translocation of glucose transporter type 4. In the pancreas, GCs provoke hyperglycemia by inhibiting glucose-stimulated insulin secretion from b-cells. Metabolic syndrome, an important risk factor for coronary artery disease, is a compilation of multiple metabolic abnormalities such as insulin resistance, hyperglycemia, dyslipidemia, obesity, and hypertension. The resemblance of the symptoms and biochemical findings between Cushing's syndrome and metabolic syndrome suggest that cortisol plays a central role in the pathogenesis and the evolution of both of these medical conditions. The vast majority of obese subjects have cortisol levels currently considered to be in the normal range, indicating that cortisol might exert a portion of its deleterious effects at the tissue level because of abnormalities of the GR and the intracellular cortisol metabolism. Therefore, mutations of the GR gene, interfering with the sensitivity of the GR to cortisol may be responsible for its varying effects in different individuals. For example, patients can develop the phenotype typically seen in Cushing's syndrome despite normal or even low serum cortisol levels. This has been described in the literature as "cortisol hyper-reactive syndrome", "glucocorticoid hypersensitivity syndrome", and "normocortisolemic Cushing's syndrome." [18] Cortisol hypersensitivity was confirmed by Iida et al. when they conducted an ex vivo study of the peripheral tissues from a patient with the manifestations of Cushing's syndrome who had extremely low cortisol levels [19] . Patients carrying polymorphisms associated with decreased receptor sensitivity to cortisol, as described later in the manuscript, have increased insulin sensitivity, lower BMI, waist circumference and LDL. Although, those polymorphisms are associated with a favorable metabolic profile, an increased incidence of autoimmune disorders is anticipated. However, studies failed to demonstrate an association with autoimmune disorders but found an increased rates of nasal Staph. Aureus [20] . Only the 9b polymorphism of the GR gene was found to have a positive association with autoimmune disorders but, despite the favorable effects of that variant on cardiometabolic parameters, carriers were found to have increased intima-media thickness and a three-fold increased rate of cardiovascular disease most likely due to a chronic pro-inflammatory state seen in those subjects as supported by the elevated levels of IL-6 and hsCRP.
An association between GR gene mutations and the manifestations of metabolic syndrome was first reported in 1992 by Weaver et al. who demonstrated that homozygous carriers of the BclI variant of GR had elevated fasting insulin and HOMA insulin resistance index [21] . Another study also found a statistically significant increase in body weight, BMI, abdominal obesity, fasting plasma glucose, insulin, and HOMA among homozygous carriers of the BclI variant [22] .
GR BclI polymorphism was found in a familial linkage study of obese (BMI > 27 kg/m2) sibling pairs and some variants were associated with higher abdominal visceral adiposity [23] . In a study of middle-aged men, the 4.5-kb BclI allele was associated with elevated waist to hip ratio, BMI and abdominal sagittal diameter [24] . However, this polymorphism did not demonstrate an association with either BMI or percent body fat in younger men (age 18-40 years old) [25] . A study of identical twins showed that the 2.3-kb homozygotes exhibit the greatest increase in body weight, abdominal adiposity and plasma cholesterol in response to overfeeding [26] . In a prospective study with a prolonged followup period, women with the GR BclI polymorphism showed a substantial increase in body weight, subcutaneous adiposity, and total body fat mass [27] .
Overnight 1-mg dexamethasone suppression testing (DST) of the BclI polymorphism carriers found them to have lower cortisol levels, suggesting an increased sensitivity to GCs with respect to the transrepression effect of cortisol on the POMC gene of the corticotroph pituitary cells [28] . The exact mechanism through which the BclI polymorphism may alter GC effects has not been determined. The BclI polymorphism does not involve a coding, regulatory or splicing region of the GR gene. Most likely this polymorphism is linked to other functionally important polymorphisms. Genotype analysis for the rs2918419 and BclI GR polymorphisms in Caucasian men performed by Syed et al. found no significant differences in wild-type BclI (G/G) vs. variant (G/C or C/C) genotype frequencies between subjects categorized by presence or absence of the metabolic syndrome or components of it. [29] In contrast, men who were homozygous or heterozygous for the rs2918419 GR polymorphism had a higher prevalence of insulin resistance and higher mean fasting insulin concentration compared to the wild type carriers. Such association, however, was not found in women, suggesting an integral role of sex hormones in the clinical implications of that GR polymorphism. Interestingly, analysis of the combined effect of rs2918419 and BclI polymorphisms showed that men with BclI variant alleles on a background of rs2918419 wild-type alleles had the lowest fasting insulin concentrations. Thus, carrying Bcl1 variant alleles alone without rs2918419 variant alleles was not associated with elevated fasting insulin concentrations. The presence of the rs2918419 variant was necessary for the association of those two intron 2 GR polymorphisms with insulin resistance. No conclusions of the rs2918419 alone on insulin resistance can be extracted from the current study since all subjects with the rs2918419 variants were carriers of the BclI variants, supporting the possibility of a locus in linkage disequilibrium with the BclI restriction site contributing to insulin resistance. With changes in cortisol levels, recent studies support the associations of BclI polymorphism with alterations of the HPA axis rather than altered anthropometric measurements, metabolic derangements and body composition [30] . Similar HPA axis alterations in association with GR and CBG gene polymorphisms, without significant differences in adipose tissue distribution, were reported in a study of prepubertal obese children [31] . However, a trend for a higher percentage of fat mass was detected in GR G/G carriers. As supported by other studies [32] , carriage of an extended intron 2 haplotype that includes the rs2918419 polymorphism downstream of the BclI site is most likely linked to hyperinsulinemia.
The opposite trend was observed in homozygous carrier of the rare Tth111I allele, although the results did not reach statistical significance. Carriers of the Tth111I variant showed elevated basal cortisol secretion and bedtime levels of salivary cortisol [33] . Evidence of partial linkage to the ER22/23EK polymorphism is associated with decreased glucocorticoid sensitivity [34] .
Another well studied polymorphism of the GR gene is the N363S variant, which is located in codon 363 of exon 2. It results from an AAT ! AGT nucleotide change. This polymorphism results in substitution of asparagine by serine. Although in vitro testing of this GR polymorphism did not show any changes in its transactivating capacity [35, 36] , increased sensitivity to GCs was found in vivo [37] . Russcher et al. reported a significant increase in transactivation of the GC response element luciferase reporter gene by the N363S variant constructed GR [38] . However, another group failed to replicate those findings but showed that in the presence and absence of dexamethasone, the N363S variant can regulate a novel set of genes compared to the wild-type GR [39] . The overnight 1-mg DST, showed no differences between N363S carriers and controls, but there was a significantly higher insulin response in N363S carriers. Using a lower dexamethasone dosage (0.25 mg) for the overnight DST, a significantly larger cortisol suppression and higher insulin response was noted in N363S carriers without differences to the number of GR or the ligand binding affinity. With respect to anthropometric measurements, a significantly higher BMI was seen in N363S carriers compared to non-carriers indicating a strong association between the N363S variant and obesity. However, larger studies have demonstrated conflicting results. A study of 491 UK Caucasian subjects found the frequency of the G allele was equal among subjects with BMI < 25 kg/m2 and BMI > 25 kg/m2 [40] , suggesting that the 1220A > G GR variant is not associated with anthropometric parameters. No association of the A-to-G point variation in exon 2 of the GR gene with obesity or cardiometabolic parameters was found in 3 subsequent studies [21, 41, 42] . The association between the 1220A > G polymorphism in exon 2 and obesity was further hampered by contradictory results, although the majority of reports were negative. Subsequent studies, in which a significantly higher mean value of BMI was found in heterozygotes for the 1220A > G polymorphism, using a different statistical analysis, (2 Â 2 tables), found that the relative risk for obesity in the 1220A > G carriers was not significantly increased [43] . This inconsistency may reflect the importance of publication bias and over-interpretation of marginal findings.
In contrast to the above mentioned GR polymorphisms associated with increased sensitivity to GCs, GR polymorphisms associated with GC resistance have been studied. The most important ones to date include the ER22/23EK (rs6189 and rs6190) and the GR-9b (rs6198).
The ER22/23EK polymorphism is located in the transactivation domain of the GR gene. A single nucleotide polymorphisms (SNPs) has been identified in both of the two adjacent codons (22 and 23) . These SNPs are fully linked and are associated with relative GC resistance [32, 44] . Although no associations with body mass index or fat mass has been found, the lean body mass was significantly higher in male carriers of the ER22/23EK polymorphism [45] . Increased muscle strength was also found in those men. In women, no statistically significant differences in BMI were found but a smaller waist circumference was observed in ER22/23EK carriers. Another striking anthropometric difference that has been observed in several studies between carriers and non-carriers of the ER22/ 23EK polymorphism is that male ER233/23EK carriers were found to be taller than non-carriers. Male ER22/23EK carriers were also found to have increased insulin sensitivity, lower fasting insulin levels, lower C-reactive protein and lower total and LDL cholesterol levels [46] .
Finally, the 9b polymorphism of the GR Gene has not been linked with BMI, adipose mass changes, waist to hip ratio, insulin sensitivity, LDL and HDL cholesterol levels. Although no significant differences were observed in anthropometric characteristics, subjects homozygous for the 9b variant had increased intima media thickness and an almost three fold increased risk for cardiovascular disease, most likely due to a subtle but chronic proinflammatory state [47] . This 9b polymorphism results in an increased expression and stabilization of GRb which functions as an active inhibitor of the active form, GRa [48] . Although the transactivation of the GR is not affected by the 9b polymorphism, transrepression is significantly reduced, and a pro-inflammatory state is expected-due to a more active immune system-in the 9b carriers [49] .
The role of glucocorticoid receptor in psychiatric illness
The deleterious psychiatric effects of chronic increased GR stimulation due to excess exogenous or endogenous GCs have been studied extensively. Even in patients administered short term GC therapy, symptoms of hypomania, depression, and even psychosis have been observed.
It has long been hypothesized that the development of psychotic symptoms in Psychotic Depression (PD) is related to increased or dysregulated systemic cortisol levels, leading to increased dopamine levels and changes to dopamine metabolism, which potentially induce psychotic symptoms in susceptible individuals [50] . Biologic findings in patients with PD related to elevated and dysregulated cortisol levels include high rates of nonsuppression on the DST [51] , reduced diurnal fluctuation of cortisol, high plasma cortisol and ACTH levels, and increased excretion of 24 h urinary free cortisol [52, 53] .
The mRNA expression of the GRa is reduced in lymphocytes of patients with major depressive disorder, both while they are depressed and when their depression is in remission. The same pattern of reduced GRa mRNA is found in first-degree relatives of patients with bipolar disorder. Those HPA axis abnormalities, at least at the GR level, could represent a trait marker for mood disorders [54] . Patients with depression and history of childhood abuse have enhanced HPA axis responses to psychosocial stress [55] and blunted adrenocorticotropin and cortisol response to lowdose dexamethasone. Those findings were not present in the nondepressed patients with a history of childhood abuse [56] . Cortisol responses to dexamethasone/CRH challenge in healthy subjects with high genetic load for affective disorders lies between the responses of healthy subjects without a family history of depression and those of depressed patients suggesting that genetic vulnerability may be intertwined with early life experience to produce to the final expression of the disease [57, 58] .
All carriers of the ER22/23EK polymorphism carry the TthIIII minor allele and demonstrate reduced GC sensitivity. An increased risk of developing depression has been reported in subjects with smaller hippocampal size which is more prevalent in homozygous carriers of the TthIIII polymorphism [59, 60] . The observation of smaller hippocampal volumes in TthIIII polymorphism carriers suggests a link between the TthIII I polymorphism and unipolar depression. Conversely, a lower prevalence of heterozygous TthIII I polymorphism carriers was found in bipolar disorder patients [61] . This may suggest a trend towards a protective effect on the clinical manifestations and course of bipolar disorder in TthIIII polymorphism carriers [55] .
The role of the ER22/23EK variant which is associated with relative resistance to GC, as shown by a reduction of transactivating capacity in vitro and less suppression of cortisol levels after 1 mg DST in vivo. Relative GC resistance associated with the ER22/23EK polymorphism might protect from the development of dementia or cognitive decline with aging. Dementia and white matter lesions were less frequent in older (over 55 years) carriers of the ER22/ 23EK variant [62] . In addition, carriers of the ER22/23EK variant had better cognitive speed tasks and less progression of subcortical lesions.
In a study of patients with depression, carrier of the ER22/23EK polymorphism had higher rates of recurrent major depression episodes and responded faster to treatment with antidepressants [63, 64] . A possible explanation could be the higher concentration of the less active GR variant which could lead to GC resistance [65] .
An association between the BclI polymorphism and major depression has been found in several studies. This variant is associated with increased sensitivity to GC. The frequency of the BclI variant was higher in patients with major depression and carriers were found to have higher ACTH levels and a worse response to antidepressant therapy [59, 66] .
The 9b polymorphism of the GR gene has been linked with a lower incidence of bipolar disorder compared to healthy subjects. A higher incidence of the 9b polymorphism has been linked with a lower frequency of hypomanic episodes in patients with bipolar disorder, suggesting a protective effect of this polymorphism [67] . As mentioned before, this variation results in increased expression and stability of GRb, functioning as a dominant negative inhibitor of the active receptor GRa.
The role of FKBP5, an important factor that controls GR sensitivity and signaling, has been increasingly recognized. The FKBP5 is a HSP90 co-chaperone that binds to GR in the cytosol and decreases the affinity of the GR for its ligand as well as the probability of the translocation of the GR-ligand complex into the nucleus. FKBP5 SNPs have been linked to a variety of psychiatric disorders including dissociative symptoms after trauma, a predictor of PTSD development in children and adult [68] . In addition, FKBP5 SNPs have been linked to recurrence of major depression and the response to antidepressants. The rs9296158 SNP has been found to be associated with a significant risk for PTSD development in subjects traumatized as children. The mechanism by which FKBP5 SNPs alter the function of the HPA axis in PTSD patients is by selectively changing cellular expression of FKBP5 and sensitivity of GR signaling. The reduction of STAT5B mRNA levels found in blood cells from PTSD patients carrying the rs9296158 SNP provides another mechanism of altered GR sensitivity [69] . Docking of the GR to a binding site on the STAT5B Nterminus inhibits GR nuclear translocation. Thereby, STAT5B deficiency could induce excessive GR signal transduction and GRmediated transcription of target genes.
Understanding that polymorphisms of the GR can lead to variable effects on psychiatric diseases, several studies have set out to evaluate a potent antagonist of GR, mifepristone, for the reduction of the psychotic symptoms of psychotic depression [70, 71] . A consistent observation from these studies reveal that 7-day administration of mifepristone appears to be effective in reducing psychotic symptoms but only when sufficient plasma levels of mifepristone are reached. Because there is significant inter-individual variability in plasma mifepristone levels due to complex pharmacokinetics, not every patient can achieve therapeutic mifepristone plasma level at a specific dose level of mifepristone. While approximately 50% of patients administered mifepristone 600 mg daily for 7 days will achieve this plasma threshold after 7 days, approximately 66% of the patients will surpass the threshold with dosing of 1200 mg for 7 days [72] . Both dosing regimens appear to be safe and well tolerated. Of note, there is also a relationship between increases in cortisol and ACTH levels after seven days of dosing and response. While mifepristone plasma levels are a predictor of response, cortisol and ACTH levels are a mediator of response to treatment (publication in press), signifying a biologically targeted therapy for the HPA dysregulation of PD.
Summary
The role and activity of the GR, which mediates the final step of cortisol action at the cellular level, is the major determinant of cortisol's effects. Polymorphisms of the GR locus associated with either increased sensitivity or resistance to GCs have been linked to metabolic syndrome and psychiatric diseases. Genetic abnormalities in proteins associated with the activity and eventual gene products of the GR can further modulate the function of the receptor leading to either resistance or increased sensitivity to GCs. Further studies, assessing the GR itself along with other factors influencing its function, are needed to investigate the complex but crucial role of GR in metabolic diseases and psychiatric illness.
